阿西鲁司特 | 943764-99-6

• 物质功能分类: 原料药
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 阿西鲁司特
• 英文名称: acebilustat
• 英文别名: 4-{[(1S,4S)-5-({4-[4-oxazol-2-yl-phenoxy]phenyl}methyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]methyl}benzoic acid；4-[[(1S,4S)-5-[[4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]methyl]-2,5-diazabicyclo[2.2.1]heptan-2-yl]methyl]benzoic acid
• CAS: 943764-99-6
• 化学式: C₂₉H₂₇N₃O₄
• 分子量: 481.551
• InChiKey: GERJIEKMNDGSCS-DQEYMECFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  36
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  79
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  methyl 4-[[(1S,4S)-5-[[4-[4-(2-oxazolyl)phenoxy]phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoate 以89的产率得到阿西鲁司特
  参考文献：
  名称：

  Diamine derivatives as inhibitors of leukotriene A4 hydrolase

  摘要：

  本发明涉及化合物的式子（I）： 其中r、q、R、R2、R3、R4、R5a、R5b、R5c、R6a、R6b、R6c、R7、R8和R9如本文所述，可以作为单一立体异构体或立体异构体混合物，或其药学上可接受的盐、溶剂合物、笼合物、多晶形、铵离子、N-氧化物或其前体；这些化合物是白三烯A4水解酶抑制剂，因此在治疗炎症性疾病方面有用。本发明还揭示了包含该化合物的制药组合物以及制备该化合物的方法。

  公开号：

  US07737145B2

文献信息

• DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE
  申请人：Celtaxsys, Inc.

  公开号：US20150080382A1

  公开（公告）日：2015-03-19

  This invention is directed to compounds of formula (I): where r, q, R, R 2 , R 3 , R 4 , R 5a , R 5b , R 5c , R 6a , R 6b , R 6c , R 7 , R 8 , and R 9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A 4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.

  该发明涉及式（I）的化合物：其中r、q、R、R2、R3、R4、R5a、R5b、R5c、R6a、R6b、R6c、R7、R8和R9如本文所述，作为单一立体异构体或立体异构体混合物，或其药学上可接受的盐、溶剂化合物、包合物、多晶体、铵离子、N-氧化物或其前药；这些化合物是白三烯A4水解酶抑制剂，因此可用于治疗炎症性疾病。本发明还公开了包含该化合物的制药组合物以及制备该化合物的方法。
• Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase
  申请人：Arnaiz Damian

  公开号：US20100210630A1

  公开（公告）日：2010-08-19

  This invention is directed to compounds of formula (I): where r, q, R, R 2 , R 3 , R 4 , R 5a , R 5b , R 5c , R 6a , R 6b , R 6c , R 7 , R 8 , and R 9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A 4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.

  本发明涉及化合物的公式(I)：其中r、q、R、R2、R3、R4、R5a、R5b、R5c、R6a、R6b、R6c、R7、R8和R9如本文所述，可以作为单一立体异构体或立体异构体混合物，或其药学上可接受的盐、溶剂合物、包合物、多晶体、铵离子、N-氧化物或前药；这些化合物是白三烯A4水解酶抑制剂，因此在治疗炎症性疾病方面有用。本发明还公开了包含该化合物的制药组合物以及制备该化合物的方法。
• [EN] METHODS OF TREATING LIVER DISEASE USING LTA4H INHIBITORS<br/>[FR] PROCÉDÉS DE TRAITEMENT D'UNE MALADIE HÉPATIQUE À L'AIDE D'INHIBITEURS DE LTA4H
  申请人：NOVARTIS AG

  公开号：WO2021044351A1

  公开（公告）日：2021-03-11

  The present disclosure relates to methods for treating or preventing a liver disease, using a LTA4H inhibitor, alone or in combination with another therapeutic agent, e.g. a FXR agonist. Also disclosed herein are LTA4H inhibitors, for treating or preventing a liver disease or disorder, as well as medicaments, dosing regimens, pharmaceutical formulations, combinations, dosage forms, and kits for use in the disclosed uses and methods.

  本公开涉及使用LTA4H抑制剂单独或与另一种治疗药物（例如FXR激动剂）联合治疗或预防肝病的方法。本公开还涉及用于治疗或预防肝病或疾病的LTA4H抑制剂，以及用于上述用途和方法的药物、剂量方案、制药配方、组合、剂型和套装。
• [EN] LTA4H INHIBITORS FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVA<br/>[FR] INHIBITEURS DE LTA4H POUR LE TRAITEMENT DE L'HIDROSADÉNITE SUPPURÉE
  申请人：NOVARTIS AG

  公开号：WO2020144604A1

  公开（公告）日：2020-07-16

  The present disclosure relates to methods for treating Hidradenitis Suppurativa using a LTA4H inhibitor. Also disclosed herein are LTA4H inhibitors, for treating Hidradenitis Suppurativa patients, as well as medicaments, dosing regimens, pharmaceutical formulations, combinations, dosage forms, and kits for use in the disclosed uses and methods.

  本公开涉及使用LTA4H抑制剂治疗汗腺炎脓肿的方法。本公开还披露了用于治疗汗腺炎脓肿患者的LTA4H抑制剂，以及用于所披露的用途和方法的药物、剂量方案、药物制剂、组合物、剂型和工具包。
• Methods of inhibiting leukotriene A4 hydrolase
  申请人：Celtaxsys, Inc.

  公开号：US10350197B2

  公开（公告）日：2019-07-16

  The present invention is directed to methods of inhibiting LTA4-h in a human patient and method of treating a condition ameliorated by the inhibition of leukotriene A4 hydrolase activity in a human patient comprising administering to said human patient the compound, 4-5-[4-(4-Oxazol-2-yl-phenoxy)-benzyl]-2,5-diaza-bicyclo[2.2.1]hept-2-ylmethyl}-benzoic acid.

  本发明涉及抑制人类患者体内 LTA4-h 的方法，以及通过抑制人类患者体内白三烯 A4 水解酶活性来改善病情的治疗方法，包括向所述人类患者施用化合物 4-5-[4-(4-噁唑-2-基-苯氧基)-苄基]-2,5-二氮杂双环[2.2.1]庚-2-基甲基}-苯甲酸。